VCNX · Vaccinex, Inc.
$1.06
At close · Dec 18
Return incl. dividend (before tax)
Going-concern doubt
— flagged Apr 15, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. Because management’s plans have not yet been finalized and are not within the Company’s control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”View the 10-K filed Apr 15, 2025
Market Cap
$2.94M
Shares
2.68M
Volume · Dec 18
94.9K
Avg daily vol (3M)
119.98K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.06
Open$1.40
Day$1.05–1.41
52W close$1.06–12.32
Avg vol 30d94K
Short int3K · 0.1% float · 2.9d
Short vol58%
DataJan 2020–Dec 2024
Filing10-K · Apr 15
Up next
filed Apr 15, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$601,000
Trailing 12 months
Net income (TTM)
−$18.63M
Trailing 12 months
Revenue growth YoY
+5.4%
Year over year
Operating margin
-3,117.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-550.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+529.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−80%
below
Price vs 50-day avg
−67%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−67%
trailing
6-month return
−84%
trailing
YTD return
−89%
this year
Relative strength
−91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -4.8% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Fundamentals
Revenue growth
+5%
Y/Y
EPS growth
+80%
Y/Y
Free cash flow
$-16.2M
Balance sheet
$1.1M
net cash
Quant / Vol
risk profile
Volatility
137%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
56.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−80%
Bearish
Price vs 50-day avg
−67%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -4.8% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $12
vs 200-day avg -80%
vs 50-day avg -67%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCNX
this stock
Vaccinex, Inc.
|
$2.94M | — | +5.4% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.14B | +15.7% | +46.2% | 31.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$98.14B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.95B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
1
- % held
- 0.0%
- Net QoQ
- -335.5K sh
- Top holder
- BARCLAYS PLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCNX | -73.8% | -67.5% | -83.7% | -72.0% | -88.5% |
| SPY | -3.5% | -0.7% | +7.7% | -2.7% | +23.4% |
| vs SPY | -70.3% | -66.8% | -91.4% | -69.3% | -111.9% |